Douglas DN - Search Results

1

Human cytomegalovirus infection in humanized liver chimeric mice.

Kawahara T, Lisboa LF, Cader S, Douglas DN, Nourbakhsh M, Pu CH, Lewis JT, Churchill TA, Humar A, Kneteman NM. Kawahara T, et al. Among authors: douglas dn. Hepatol Res. 2013 Jun;43(6):679-84. doi: 10.1111/j.1872-034X.2012.01116.x. Epub 2013 Feb 26. Hepatol Res. 2013. PMID: 23442000

2

Mice with Chimeric Human Livers and Their Applications.

Douglas DN, Kneteman NM. Douglas DN, et al. Methods Mol Biol. 2019;1911:459-479. doi: 10.1007/978-1-4939-8976-8_32. Methods Mol Biol. 2019. PMID: 30593646 Review.

3

Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.

Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, Aukerman L, Kovelsky R, Ni ZJ, Zhu Q, Hashash A, Kline J, Hsi B, Schiller D, Douglas D, Tyrrell DL, Mercer DF. Kneteman NM, et al. Hepatology. 2006 Jun;43(6):1346-53. doi: 10.1002/hep.21209. Hepatology. 2006. PMID: 16729319

4

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.

Kneteman NM, Howe AY, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DL, Immermann F, Chaudhary I, Speth J, Villano SA, O'Connell J, Collett M. Kneteman NM, et al. Hepatology. 2009 Mar;49(3):745-52. doi: 10.1002/hep.22717. Hepatology. 2009. PMID: 19072827 Clinical Trial.

5

Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection.

Kneteman NM, Asthana S, Lewis J, Dibben C, Douglas D, Nourbakhsh M, Tyrrell LJ, Lund G. Kneteman NM, et al. Liver Transpl. 2012 Jan;18(1):38-44. doi: 10.1002/lt.22400. Liver Transpl. 2012. PMID: 21837737 Free article.

6

Characterization of lipid and lipoprotein metabolism in primary human hepatocytes.

Ling J, Lewis J, Douglas D, Kneteman NM, Vance DE. Ling J, et al. Biochim Biophys Acta. 2013 Feb;1831(2):387-97. doi: 10.1016/j.bbalip.2012.08.012. Epub 2012 Aug 23. Biochim Biophys Acta. 2013. PMID: 22951416

7

Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production.

Nourbakhsh M, Douglas DN, Pu CH, Lewis JT, Kawahara T, Lisboa LF, Wei E, Asthana S, Quiroga AD, Law LM, Chen C, Addison WR, Nelson R, Houghton M, Lehner R, Kneteman NM. Nourbakhsh M, et al. Among authors: douglas dn. J Hepatol. 2013 Aug;59(2):336-43. doi: 10.1016/j.jhep.2013.03.022. Epub 2013 Mar 28. J Hepatol. 2013. PMID: 23542347

8

Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma.

Kawahara T, Toso C, Yamaguchi K, Cader S, Douglas DN, Nourbakhsh M, Lewis JT, Churchill TA, Yagita H, Kneteman NM. Kawahara T, et al. Among authors: douglas dn. Liver Int. 2013 Oct;33(9):1441-8. doi: 10.1111/liv.12275. Epub 2013 Jul 29. Liver Int. 2013. PMID: 23895107

9

Generation of improved mouse models for the study of hepatitis C virus.

Douglas DN, Kneteman NM. Douglas DN, et al. Eur J Pharmacol. 2015 Jul 15;759:313-25. doi: 10.1016/j.ejphar.2015.03.022. Epub 2015 Mar 23. Eur J Pharmacol. 2015. PMID: 25814250 Review.

10

Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease.

Douglas DN, Kawahara T, Sis B, Bond D, Fischer KP, Tyrrell DL, Lewis JT, Kneteman NM. Douglas DN, et al. PLoS One. 2010 Feb 18;5(2):e9209. doi: 10.1371/journal.pone.0009209. PLoS One. 2010. PMID: 20174638 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page